Novartis's Cosentyx adds to Stelara's data woes

Johnson & Johnson's Stelara (ustekinumab) has received its second drubbing in recent weeks in head-to-head studies with rival anti-inflammatories in plaque psoriasis. Novartis says that top-line data from the Phase III CLEAR study show that its new anti-IL17A monoclonal secukinumab (Cosentyx) was better than Stelara in clearing the skin, and it met its primary endpoint.